Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

375.94
+11.363.12%
Pre-market: 378.502.56+0.68%06:36 EDT
Volume:413.32K
Turnover:156.34M
Market Cap:10.47B
PE:-29.23
High:387.99
Open:370.35
Low:365.37
Close:364.58
52wk High:392.70
52wk Low:37.19
Shares:27.85M
Float Shares:24.08M
Volume Ratio:1.02
T/O Rate:1.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:7.81
PE(LYR):-27.90

Loading ...

Can Praxis Precision Medicines (PRAX) Merit A Higher Valuation As It Expands Ulixacaltamide Delivery?

Simply Wall St.
·
Jul 10

Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says

MT Newswires Live
·
Jul 10

Praxis Precision, Remagine Labs Partner on Ulixacaltamide Patch

TIPRANKS
·
Jul 08

Praxis Precision Medicines Makes Equity Investment in Remagine Labs

Reuters
·
Jul 07

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

THOMSON REUTERS
·
Jul 07

S&P 500 Futures Climb in Premarket Trading; Praxis Precision Meds, IREN Lead

Dow Jones
·
Jul 06

Praxis Precision Medicines Switches Auditor to KPMG from EY

Reuters
·
Jul 03

Praxis Precision Medicines Grants 951 Restricted Stock Units to Five New Employees Under Inducement Plan

Reuters
·
Jul 03

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jul 03

Movement Alert|Praxis Precision Medicines Falls 5.15% in Regular Trading, FDA Extends Relutrigine Review Period by Three Months

Market Focus
·
Jul 02

Analysts Are Bullish on These Healthcare Stocks: Praxis Precision Medicines (PRAX), Aurora Cannabis (ACB)

TIPRANKS
·
Jul 01

Praxis Precision Medicines (PRAX) Receives a Buy from Guggenheim

TIPRANKS
·
Jun 30

Analysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)

TIPRANKS
·
Jun 30

Praxis Precision Medicines (PRAX) Receives a Buy from TD Cowen

TIPRANKS
·
Jun 30

Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines

Dow Jones
·
Jun 30

FDA Extends Review Timeline for Praxis’ Relutrigine NDA

TIPRANKS
·
Jun 30

Praxis Precision Medicines Says FDA Extends Review of Relutrigine Application

Dow Jones
·
Jun 30

Praxis Precision Medicines - FDA Extends Review Period for Relutrigine Nda for Scn2a and Scn8a Dees by Three Months

THOMSON REUTERS
·
Jun 30

Praxis Precision Medicines - FDA Sets Updated Pdufa Date of December 27, 2026 for Relutrigine

THOMSON REUTERS
·
Jun 30

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

GlobeNewswire
·
Jun 30